Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
|Articles|July 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
Zosyn Is Cleared for Treatment Of Nosocomial Pneumonia
ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam) is now indicated for use in treating moderate to severe nosocomial pneumonia caused by piperacillin-resistant beta-lactamase-producing strains of Staphylococcus aureus. In a multicenter study of 300 patients with nosocomial pneumonia, the rate of clinical cure or improvement for Zosyn plus tobramycin was 74%, compared with 50% for cef-tazidime plus tobramycin, the company said.
Advertisement
ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam)is now indicated for use in treating moderate to severe nosocomialpneumonia caused by piperacillin-resistant beta-lactamase-producingstrains of Staphylococcus aureus. In a multicenter study of 300patients with nosocomial pneumonia, the rate of clinical cureor improvement for Zosyn plus tobramycin was 74%, compared with50% for cef-tazidime plus tobramycin, the company said.
Articles in this issue
about 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchabout 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentabout 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%about 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsabout 30 years ago
Trimetrexate Appears Beneficial in Colorectal Cancerabout 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsabout 30 years ago
New Company Joins With RPR To Develop Intrabody Technologyabout 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataabout 30 years ago
CDC Says Teen Smoking Still RisingAdvertisement
Related to this article
Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
ASTRO Issues First Clinical Practice Guideline on Radiation for Bladder Cancer
4
KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors
5